Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Provided herein are Stimulator of Interferon Genes (STING) ligand for use in enhancing immune response and/or as adjuvants in vaccines. In some embodiments, STING ligand is used alone or in combination with Alum in an adjuventation system for early life immunization.

Abstract: Provided herein are Toll-like receptor 2 (TLR2) agonists for use in enhancing human immune response and/or as adjuvants in vaccines. The TLR2 agonists include thiophenes, imidazoles, or phenyl-containing compounds, which may be compounds of Formulae (I), (II), (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.

Abstract: Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave T cells to differentiate into IFN-?-producing T cells, and for preventing and treating infections. The combinatorial composition comprises TLR and CLR agonists. The combinatorial composition comprises at least one TLR4 agonist and at least one Dectin-1 agonist, wherein the at least TLR4 agonist is monophosphoryl lipid A (MPLA) or glycopyranosyl lipid A (GLA), or the combinatorial composition comprises at least one TLR7/8 agonist and at least one Mincle agonist.

Abstract: The present invention is directed to PVRIG polypeptides and their uses.

Abstract: The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.

Abstract: A processor includes a front end including circuitry to decode an instruction from an instruction stream and a core including circuitry to process the instruction. The core includes an execution pipeline, a dynamic core frequency logic unit, and a counter compensation logic unit. The execution pipeline includes circuitry to execute the instruction. The dynamic core frequency logic unit includes circuitry to squash a clock of the core to reduce a core frequency. The clock may not be visible to software. The counter compensation logic unit includes circuitry to adjust a performance counter increment associated with a performance counter based on at least the dynamic core frequency logic unit circuitry to squash a clock of the core to reduce a core frequency.

Abstract: Provided herein are imidazopyrimidine compounds for use in enhancing human immune response and/or as adjuvants in vaccines.

Abstract: A monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an isolated polypeptide comprising amino acids of the soluble ectodomain of a sequence selected from the group consisting of SEQ ID NOs:3 and 5, or a fragment, thereof, or an epitope thereof; for use in treatment of cancer, wherein immune cells in the microenvironment of said cancer express said isolated polypeptide.

Abstract: A delivery device includes a guide tool and an impact tool. The guide tool includes an elongate body formed with a longitudinal guide channel, whose inner perimeter is made to complement an outer contour of an implant. The elongate body is formed with a longitudinal impact-tool channel, whose inner perimeter is made to complement an outer contour of the impact tool.

Abstract: Artificial tissue constructs (TCs), methods of making the TCs, uses thereof, and kits comprising the TCs are provided. TCs are useful for vaccine evaluation for human adult, human non-newborn, and newborns.

Abstract: A processor includes a counter to store a cycle count that tracks a number of cycles between retirement of a first branch instruction and retirement of a second branch instruction during execution of a set of instructions. The processor further includes a stack of registers coupled to the counter, wherein the stack of registers is to store branch type information including: a first value of the counter when the first branch instruction is retired; a second value of the counter when the second branch instruction is retired; a first type information value indicating a type of the first branch instruction; and a second type information value indicating a type of the second branch instruction.

Abstract: The methods and compositions described herein relate to methods of immunization or stimulating an immune response, e.g., using agonists of TLR7 and/or TLR8 as antigens. The methods and compositions described herein have particular relevance to use in infants.

Abstract: An example processor that includes a decoder, an execution circuit, a counter, and a last branch recorder (LBR) register. The decoder may decode a branch instruction for a program. The execution circuit may be coupled to the decoder, where the execution circuit may execute the branch instruction. The counter may be coupled to the execution circuit, where the counter may store a cycle count. The LBR register coupled to the execution circuit, where the LBR register may include a counter field to store a first value of the counter when the branch instruction is executed and a type field to store type information indicating a type of the branch instruction.

Abstract: The present invention is directed to PVRIG polypeptides and their uses.

Abstract: A facet distraction prosthesis includes an array of facet distraction base elements, connected to each other by a set of connector elements located at adjacent base elements. The set of connector elements includes a male connector having an at least partial cylindrical or spherical contour that is received in, and articulates with, an at least partial cylindrical or spherical recess of a female connector, so that adjacent ones of the base elements can bend in multiple degrees of freedom about different bending axes with respect to each other and adapt to a geometry of a facet joint.

Abstract: A composition of matter is disclosed which comprises crosslinked collagen, platelet rich plasma (PRP) and an inorganic salt. Methods of generating same and uses thereof are also disclosed.

Abstract: A device implementing a system for coexistence of collocated radios may include a first radio circuit configured to receive, from a collocated second radio circuit, a start indication for cellular activity associated with a radio resource control connection. The first radio circuit may be configured to, responsive to receiving the start indication, stop a wireless transmission capability. The first radio circuit may be configured to receive, from the collocated cellular circuit, an end indication for the cellular activity prior to the radio resource control connection being released. The first radio circuit may be configured to resume the wireless transmission capability in accordance with a reduced power level response to receiving the end indication.

Abstract: A processor of an aspect includes a decode unit to decode a thread pause instruction from a first thread. A back-end portion of the processor is coupled with the decode unit. The back-end portion of the processor, in response to the thread pause instruction, is to pause processing of subsequent instructions of the first thread for execution. The subsequent instructions occur after the thread pause instruction in program order. The back-end portion, in response to the thread pause instruction, is also to keep at least a majority of the back-end portion of the processor, empty of instructions of the first thread, except for the thread pause instruction, for a predetermined period of time. The majority may include a plurality of execution units and an instruction queue unit.

Abstract: In an embodiment, a processor for Return Oriented Programming (ROP) detection includes at least one execution unit; a plurality of event counters, each event counter associated with a unique type of a plurality of types of control transfer events; and a ROP detection unit. The ROP detection unit may be to: adjust a first event counter in response to detection of a first type of control transfer events; in response to a determination that the first event counter exceeds a first threshold, access a first configuration register associated with the first event counter to read configuration data; identify a set of ROP heuristic checks based on the configuration data read from the first configuration register; and perform each ROP heuristic check of the identified set of ROP heuristic checks. Other embodiments are described and claimed.